{"id":"NCT01984424","sponsor":"Amgen","briefTitle":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","officialTitle":"A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-10","primaryCompletion":"2015-11-10","completion":"2017-11-21","firstPosted":"2013-11-14","resultsPosted":"2018-03-13","lastUpdate":"2018-11-29"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia"],"interventions":[{"type":"DRUG","name":"Atorvastatin","otherNames":["Lipitor"]},{"type":"DRUG","name":"Placebo to Atorvastatin","otherNames":[]},{"type":"OTHER","name":"Placebo to Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Ezetimibe","otherNames":["Zetia"]},{"type":"OTHER","name":"Placebo to Evolocumab","otherNames":[]},{"type":"DRUG","name":"Evolocumab","otherNames":["Repatha"]}],"arms":[{"label":"Part A: Atorvastatin 20 mg => Placebo","type":"OTHER"},{"label":"Part A: Placebo => Atorvastatin 20 mg","type":"OTHER"},{"label":"Part B: Ezetimibe","type":"ACTIVE_COMPARATOR"},{"label":"Part B: Evolocumab","type":"EXPERIMENTAL"},{"label":"Part C: Open-label Evolocumab","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).","primaryOutcome":{"measure":"Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24","timeFrame":"Baseline and weeks 22 and 24","effectByArm":[{"arm":"Ezetimibe","deltaMin":-16.7,"sd":1.91},{"arm":"Evolocumab","deltaMin":-54.5,"sd":1.39}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":58,"countries":["United States","Australia","Canada","Czechia","Denmark","France","Germany","Italy","Netherlands","New Zealand","Norway","South Africa","United Kingdom"]},"refs":{"pmids":["30073585","33078867","27039291"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":145},"commonTop":["Myalgia","Muscle spasms","Fatigue","Headache","Nasopharyngitis"]}}